Published in J Vasc Res on August 01, 2000
Thrombospondins in cancer. Cell Mol Life Sci (2008) 2.08
Trans-arachidonic acids generated during nitrative stress induce a thrombospondin-1-dependent microvascular degeneration. Nat Med (2005) 1.91
NF-kappaB balances vascular regression and angiogenesis via chromatin remodeling and NFAT displacement. Blood (2010) 1.64
Biology of angiogenesis and invasion in glioma. Neurotherapeutics (2009) 1.61
Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. Am J Pathol (2001) 1.45
Biomedicine and diseases: the Klippel-Trenaunay syndrome, vascular anomalies and vascular morphogenesis. Cell Mol Life Sci (2005) 1.37
The effect of thrombospondin-1 on breast cancer metastasis. Breast Cancer Res Treat (2008) 1.32
Thrombospondin-based antiangiogenic therapy. Microvasc Res (2007) 1.26
Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol Biol Cell (2002) 1.26
Identification of thrombospondin 1 (TSP-1) as a novel mediator of cell injury in kidney ischemia. J Clin Invest (2005) 1.19
Thrombospondin 2 regulates cell proliferation induced by Rac1 redox-dependent signaling. Mol Cell Biol (2003) 1.16
Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer (2010) 1.14
New molecular targets in angiogenic vessels of glioblastoma tumours. Expert Rev Mol Med (2008) 1.08
Tumor angiogenesis: insights and innovations. J Oncol (2010) 1.04
Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. Mol Biol Cell (2007) 1.03
Thrombospondin-1-induced apoptosis of brain microvascular endothelial cells can be mediated by TNF-R1. J Cell Physiol (2009) 1.00
A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. Cancer Res (2009) 0.99
Level of endothelial cell apoptosis required for a significant decrease in microvessel density. Exp Cell Res (2007) 0.98
Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments. Curr Drug Targets (2008) 0.97
Transcription and splicing regulation in human umbilical vein endothelial cells under hypoxic stress conditions by exon array. BMC Genomics (2009) 0.97
Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase. Blood (2011) 0.95
Enhanced angiogenesis and reduced contraction in thrombospondin-2-null wounds is associated with increased levels of matrix metalloproteinases-2 and -9, and soluble VEGF. J Histochem Cytochem (2008) 0.94
Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy. Neuro Oncol (2005) 0.94
Thrombospondin-1 and CD47 regulation of cardiac, pulmonary and vascular responses in health and disease. Matrix Biol (2014) 0.90
The response of VEGF-stimulated endothelial cells to angiostatic molecules is substrate-dependent. BMC Cell Biol (2005) 0.88
Tumor angiogenesis as a target for dietary cancer prevention. J Oncol (2011) 0.86
Activation of Latent TGF-β1 by Thrombospondin-1 is a Major Component of Wound Repair. Oral Biosci Med (2005) 0.86
Sensitization of breast cancer cells to taxol by inhibition of taxol resistance gene 1. Oncol Lett (2011) 0.85
Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular Matrix. Pharmaceuticals (Basel) (2011) 0.84
Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells. Biochem Pharmacol (2007) 0.84
Cellular immunotherapy for ovarian cancer. Expert Opin Biol Ther (2009) 0.83
Higher plasma thrombospondin-1 levels in patients with coronary artery disease and diabetes mellitus. Korean Circ J (2012) 0.81
Chronic delivery of a thrombospondin-1 mimetic decreases skeletal muscle capillarity in mice. PLoS One (2013) 0.80
Pregnancy-associated genes contribute to antiluteolytic mechanisms in ovine corpus luteum. Physiol Genomics (2013) 0.80
Thrombospondin 1 in hypoxia-conditioned media blocks the growth of human microvascular endothelial cells and is increased in systemic sclerosis tissues. Fibrogenesis Tissue Repair (2011) 0.79
Anti-angiogenic effects of the thienopyridine SR 25989 in vitro and in vivo in a murine pulmonary metastasis model. Br J Cancer (2002) 0.79
Caffeine-induced endothelial cell death and the inhibition of angiogenesis. Anat Cell Biol (2013) 0.77
Novel human-derived extracellular matrix induces in vitro and in vivo vascularization and inhibits fibrosis. Biomaterials (2015) 0.76
Divergent regulation of angiopoietin-1 and -2, Tie-2, and thrombospondin-1 expression by estrogen in the baboon endometrium. Mol Reprod Dev (2010) 0.76
Biochemical Changes in the Niche Following Tumor Cell Invasion. J Cell Biochem (2016) 0.75
Tumor Vascular Morphology Undergoes Dramatic Changes during Outgrowth of B16 Melanoma While Proangiogenic Gene Expression Remains Unchanged. ISRN Oncol (2011) 0.75
Dynamic Perfusion Culture of Human Outgrowth Endothelial Progenitor Cells on Demineralized Bone Matrix In Vitro. Med Sci Monit (2016) 0.75
Thrombospondin-1 inhibits ossification of tissue engineered cartilage constructed by ADSCs. Am J Transl Res (2017) 0.75
Thrombospondin-1 Gene Deficiency Worsens the Neurological Outcomes of Traumatic Brain Injury in Mice. Int J Med Sci (2017) 0.75
Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science (1992) 7.92
Hydrogels for tissue engineering. Chem Rev (2001) 7.25
Polymeric system for dual growth factor delivery. Nat Biotechnol (2001) 7.20
Biological action of leptin as an angiogenic factor. Science (1998) 6.02
A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A (1990) 5.26
Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature (1987) 5.24
The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem (1995) 4.77
Alginate hydrogels as synthetic extracellular matrix materials. Biomaterials (1999) 4.69
Propagation of a human herpesvirus from AIDS-associated Kaposi's sarcoma. N Engl J Med (1997) 3.90
Activated macrophages induce vascular proliferation. Nature (1977) 3.74
Keratinocytes as initiators of inflammation. Lancet (1991) 3.68
DNA delivery from polymer matrices for tissue engineering. Nat Biotechnol (1999) 3.37
Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol (1999) 3.15
Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol (1993) 3.15
Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature (1995) 3.07
Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol (1998) 3.05
Molecular mechanisms of accommodation in Escherichia coli to toxic levels of Cd2+. J Bacteriol (1975) 2.95
Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science (1995) 2.88
Engineering and characterization of functional human microvessels in immunodeficient mice. Lab Invest (2001) 2.61
Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell (1989) 2.27
Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol (1991) 2.24
Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest (1996) 2.24
Open pore biodegradable matrices formed with gas foaming. J Biomed Mater Res (1998) 2.22
Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest (1996) 2.20
Controlled growth factor release from synthetic extracellular matrices. Nature (2001) 2.15
Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med (1996) 2.14
Interleukin-8. A corneal factor that induces neovascularization. Am J Pathol (1992) 2.08
Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med (1994) 2.05
Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest (1984) 2.04
Development of biocompatible synthetic extracellular matrices for tissue engineering. Trends Biotechnol (1998) 2.01
Cell-interactive alginate hydrogels for bone tissue engineering. J Dent Res (2001) 1.95
Discordant expression of CD28 ligands, BB-1, and B7 on keratinocytes in vitro and psoriatic cells in vivo. Am J Pathol (1993) 1.94
Cyclic mechanical strain regulates the development of engineered smooth muscle tissue. Nat Biotechnol (1999) 1.94
Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. J Thromb Haemost (2007) 1.92
Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res (2001) 1.92
Degradation of partially oxidized alginate and its potential application for tissue engineering. Biotechnol Prog (2001) 1.91
Regulating bone formation via controlled scaffold degradation. J Dent Res (2003) 1.72
Stimulation of neovascularization by human rheumatoid synovial tissue macrophages. Arthritis Rheum (1986) 1.71
Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem Biophys Res Commun (1995) 1.71
Endothelial proliferation in the delayed hypersensitivity reaction: an autoradiographic study. J Immunol (1977) 1.67
Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet (1994) 1.66
Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism. Proc Natl Acad Sci U S A (1994) 1.65
Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J Leukoc Biol (1995) 1.64
Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J Invest Dermatol (1994) 1.63
Integrin binding and cell spreading on extracellular matrix act at different points in the cell cycle to promote hepatocyte growth. Mol Biol Cell (1994) 1.61
Inhibition of 125I-epidermal growth factor binding to cultured keratinocytes by antiproliferative molecules gamma interferon, cyclosporin A, and transforming growth factor-beta. J Invest Dermatol (1989) 1.55
Transforming growth factor-beta (TGF beta) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem Biophys Res Commun (1988) 1.54
Marked synergism between tumor necrosis factor-alpha and interferon-gamma in regulation of keratinocyte-derived adhesion molecules and chemotactic factors. J Clin Invest (1990) 1.54
The role of CXC chemokines as regulators of angiogenesis. Shock (1995) 1.52
Sustained release of vascular endothelial growth factor from mineralized poly(lactide-co-glycolide) scaffolds for tissue engineering. Biomaterials (2000) 1.52
Expression of interleukin-1beta in human breast carcinoma. Cancer (1997) 1.52
Thrombospondin 1 synthesis and function in wound repair. Am J Pathol (1996) 1.52
Cadmium-binding component in Escherichia coli during accommodation to low levels of this ion. Appl Environ Microbiol (1981) 1.49
Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res (2000) 1.46
Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ (1998) 1.44
Accessory cell function of keratinocytes for superantigens. Dependence on lymphocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. J Immunol (1993) 1.42
Injection molding of chondrocyte/alginate constructs in the shape of facial implants. J Biomed Mater Res (2001) 1.42
NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chem (2001) 1.39
Unusual presentation of a chondromyxoid fibroma of the mandible. Report of a case and review of the literature. Oral Surg Oral Med Oral Pathol (1993) 1.39
Bioabsorbable polymer scaffolds for tissue engineering capable of sustained growth factor delivery. J Control Release (2000) 1.36
Growth of continuous bonelike mineral within porous poly(lactide-co-glycolide) scaffolds in vitro. J Biomed Mater Res (2000) 1.35
Bone regeneration in a rat cranial defect with delivery of PEI-condensed plasmid DNA encoding for bone morphogenetic protein-4 (BMP-4). Gene Ther (2005) 1.35
Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol (1994) 1.34
Thrombospondin-induced adhesion of human keratinocytes. J Clin Invest (1988) 1.33
Modulation of JE/MCP-1 expression in dermal wound repair. Am J Pathol (1995) 1.33
The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukoc Biol (1997) 1.32
Protein synthesis in Escherichia coli during recovery from exposure to low levels of Cd2+. Appl Environ Microbiol (1984) 1.32
Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res (1994) 1.32
Assay and purification of naturally occurring inhibitor of angiogenesis. Methods Enzymol (1991) 1.31
Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res (1995) 1.30
Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Physiol (1999) 1.30
Single-strand breakage in DNA of Escherichia coli exposed to Cd2+. J Bacteriol (1978) 1.29
Modulation of keratinocyte motility. Correlation with production of extracellular matrix molecules in response to growth promoting and antiproliferative factors. Am J Pathol (1988) 1.29
Decreased growth inhibition by recombinant gamma interferon is associated with increased transforming growth factor-alpha production in keratinocytes cultured from psoriatic lesions. Br J Dermatol (1989) 1.26
Control of microtubule assembly by extracellular matrix and externally applied strain. Am J Physiol Cell Physiol (2001) 1.25
Bone regeneration via a mineral substrate and induced angiogenesis. J Dent Res (2004) 1.25
Modulation of keratinocyte-derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes. Am J Pathol (1991) 1.24
Engineered bone development from a pre-osteoblast cell line on three-dimensional scaffolds. Tissue Eng (2000) 1.23
Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am J Pathol (1997) 1.23
Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res (1996) 1.23
Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol (1994) 1.21
Downregulation of endothelial cell thrombospondin 1 enhances in vitro angiogenesis. J Vasc Res (1994) 1.20
Release from alginate enhances the biological activity of vascular endothelial growth factor. J Biomater Sci Polym Ed (1998) 1.20
Basic fibroblast growth factor mediates angiogenic activity in early surgical wounds. Surgery (1996) 1.20
Optimizing seeding and culture methods to engineer smooth muscle tissue on biodegradable polymer matrices. Biotechnol Bioeng (1998) 1.19
Transplanted endothelial cells enhance orthotopic bone regeneration. J Dent Res (2006) 1.18
Welding arc maculopathy and fluphenazine. Br J Ophthalmol (1991) 1.17
Biochemical and functional abnormalities of left and right ventricular function after ultra-endurance exercise. Heart (2007) 1.17
Engineered smooth muscle tissues: regulating cell phenotype with the scaffold. Exp Cell Res (1999) 1.16
Successful treatment of infantile hemangiomas with interferon-alpha-2b. J Pediatr Hematol Oncol (1997) 1.16
Scaffolds for engineering smooth muscle under cyclic mechanical strain conditions. J Biomech Eng (2000) 1.11
Tissue engineering using synthetic extracellular matrices. Nat Med (1996) 1.11
Craniofacial tissue engineering. Crit Rev Oral Biol Med (2001) 1.11
Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice. Lab Invest (1997) 1.10